切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2025, Vol. 14 ›› Issue (02) : 124 -135. doi: 10.3877/cma.j.issn.2095-3224.2025.02.003

指南与共识

原发性小肠肿瘤多学科综合治疗中国专家共识(2025版)
中国医师协会结直肠肿瘤专业委员会   
  • 收稿日期:2025-03-02 出版日期:2025-04-25
  • 基金资助:
    四大慢病重大专项(No. 2024ZD0520303)

Chinese expert consensus on multidisciplinary comprehensive treatment of small intestinal tumors (2025 Edition)

Cancer Professional Committee of the Chinese Medical Doctor Association Colorectal   

  • Received:2025-03-02 Published:2025-04-25
引用本文:

中国医师协会结直肠肿瘤专业委员会. 原发性小肠肿瘤多学科综合治疗中国专家共识(2025版)[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(02): 124-135.

Cancer Professional Committee of the Chinese Medical Doctor Association Colorectal. Chinese expert consensus on multidisciplinary comprehensive treatment of small intestinal tumors (2025 Edition)[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2025, 14(02): 124-135.

近年来,小肠肿瘤作为一种罕见消化道肿瘤,发病率呈持续上升。因其临床表现非特异性,容易与其他消化道疾病混淆,导致早期难以察觉,延误率高,而且临床诊疗可供参考的证据非常有限。在此背景下,中国医师协会结直肠肿瘤专业委员会组织多学科专家针对小肠肿瘤的临床特点、诊断标准、治疗原则和随访监测,综合国内外研究和临床实践,编撰形成小肠肿瘤多学科综合治疗专家共识(2025版),旨在提升小肠肿瘤的综合诊疗水平。

Small intestinal tumors,as a rare type of gastrointestinal tumor,have shown a continuous increase in incidence recent years. Due to the nonspecific clinical manifestations,it is easily confused with other gastrointestinal diseases,leading to difficulties in early detection and a high rate of delayed diagnosis. Moreover,the clinical diagnosis and treatment of small intestinal tumors are severely limited by the scarcity of available evidence. Therefore,the Colorectal Tumor Professional Committee of the Chinese Medical Doctor Association has organized multidisciplinary experts to compile the Chinese expert consensus on multidisciplinary comprehensive treatment of small intestinal tumors (2025 Edition).This consensus integrates domestic and international research and clinical practice,focusing on the clinical characteristics,diagnostic criteria,treatment principles,and follow-up monitoring of small intestinal tumors.It aims to enhance the comprehensive diagnosis and treatment level of small intestinal tumors.

表1 病理学诊断报告参数[19]
成员(按姓氏拼音首字母排序)
顾问 王锡山
组长 董 超 于冠宇
委员(按姓氏拼音首字母排序)
曹跃鹏 宁波大学附属第一医院
董 超 昆明医科大学第一附属医院
高兆亚 北京大学首钢医院
顾国利 空军特色医学中心
胡孔旺 安徽医科大学第一附属医院
贾漪涛 河北省人民医院肿瘤科
姜 争 中国医学科学院肿瘤医院
柯 嘉 中山大学附属第六医院
李大卫 复旦大学附属肿瘤医院
李 海 宁夏医科大学总院附属医院
李中信 河北医科大学第一医院
廖传文 江西省人民医院
刘东宁 南昌大学附属第一医院
刘恒昌 中国医学科学院肿瘤医院
刘 琪 哈尔滨医科大学附属第一医院
刘艳芳 海军军医大学第一附属医院
乔天宇 哈尔滨医科大学附属第二医院
权继传 中国医学科学院肿瘤医院
尚国印 哈尔滨医科大学附属第一医院
王锡山 中国医学科学院肿瘤医院
王枭杰 福建医科大学附属协和医院
王志刚 上海市第六人民医院
吴元玉 吉林大学中日联谊医院
熊 斌 武汉大学中南医院
徐洪伟 哈尔滨医科大学附属第二医院
许剑民 复旦大学附属中山医院
燕 东 甘肃省人民医院
杨 辉 山东第一医科大学第一附属医院
姚宏亮 中南大学湘雅二医院
尹叶锋 中国医学科学院肿瘤医院
于冠宇 海军军医大学第一附属医院
俞少俊 浙江大学第二附属医院
郁 雷 哈尔滨医科大学附属第二医院
张浩鹏 哈尔滨医科大学附属第四医院
张伟华 甘肃省肿瘤医院
张新生 大连医科大学附属第二医院
赵志勋 中国医学科学院肿瘤医院
庄成乐 上海市第十人民医院
庄 競 河南省肿瘤医院
执笔人 尹叶锋 董 超 于冠宇
[1]
Siegel RL,Giaquinto AN,Jemal A. Cancer statistics,2024[J]. CA Cancer J Clin,2024,74(1):12-49.
[2]
Huang JJ,Chan SC,Fung YC,et al. Incidence,risk factors,and temporal trends of small intestinal cancer:a global analysis of cancer registries[J]. Gastroenterology,2023,165(3):600-612.
[3]
廖绪亮,朱云峰,张维汉,等. 单中心220例小肠肿瘤临床病理学特征和预后因素分析[J]. 中华胃肠外科杂志,2023,26(5):467-474.Liao XL,Zhu YF,Zhang WH,et al. Clinicopathological characteristics and prognosis of patients with small bowel tumors:a single center analysis of 220 cases[J]. Chin J Gastrointest Surg,2023,26(5):467-474.
[4]
Antonescu CR. Targeted therapy of cancer:new roles for pathologists in identifying GISTs and other sarcomas [J]. Mod Pathol,2008,21(Suppl. 2):S31-36.
[5]
Ishikawa T,Kanda T,Kosugi S,et al. Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors[J]. Gan To Kagaku Ryoho,2011,38(6):916-921.
[6]
Alshehri SA,Hussein MRA. Primary localized amyloidosis of the intestine:a pathologist viewpoint[J]. Gastroenterology Res,2020,13(4):129-137.
[7]
Bennett CM,Coleman HG,Veal PG,et al. Lifestyle factors and small intestine adenocarcinoma risk:a systematic review and metaanalysis[J]. Cancer Epidemiol,2015,39(3):265-273.
[8]
Aparicio T,Pachev A,Laurent-Puig P,et al. Epidemiology,risk factors and diagnosis of small bowel adenocarcinoma[J]. Cancers (Basel),2022,14(9):2268.
[9]
Algaba A,Guerra I,Marín-jiménez I,et al. Incidence,management,and course of cancer in patients with inflammatory bowel disease[J]. J Crohns Colitis,2015,9(4):326-333.
[10]
Cahill C,Gordon PH,Petrucci A,et al. Small bowel adenocarcinoma and Crohn's disease:any further ahead than 50 years ago?[J]. World J Gastroentero,2014,20(33):11486-11495.
[11]
Grolleau C,Pote NM,Guedj NS,et al. Small bowel adenocarcinoma complicating Crohn's disease:a single-centre experience emphasizing the importance of screening for dysplasia[J]. Virchows Arch,2017,471(5):611-617.
[12]
Palascak-juif V,Bouvier AM,Cosnes J,et al. Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo[J]. Inflamm Bowel Dis,2005,11(9):828-832.
[13]
Howdle PD,Jalal PK,Holmes GK,et al. Primary small-bowel malignancy in the UK and its association with coeliac disease[J]. QJM,2003,96(5):345-353.
[14]
De Rosa M,Pace U,Rega D,et al. Genetics,diagnosis and management of colorectal cancer[J]. Oncol Rep,2015,34(3):1087-1096.
[15]
Shenoy S. Genetic risks and familial associations of small bowel carcinoma[J]. World J Gastro Oncol,2016,8(6):509-519.
[16]
Barsouk A,Rawla P,Barsouk A,et al. Epidemiology of cancers of the small intestine:trends,risk factors,and prevention[J]. Med Sci (Basel),2019,7(3):46.
[17]
Moller P,Seppälät T,Bernstein I,et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age:a report from the Prospective Lynch Syndrome Database[J]. Gut,2018,67(7):1306-1316.
[18]
Giardiello FM,Brensinger JD,Tersmette AC,et al. Very high risk of cancer in familial Peutz-Jeghers syndrome[J]. Gastroenterology,2000,119(6):1447-1453.
[19]
NCCN Clinical Practice Guidelines in Oncology. NCCN guidelines version 2.2025-small bowel adenocarcinoma[EB/OL].(2025-01-17)[2025-03-02] https://www.nccnchina.org.cn/guide/detail/802.
[20]
Nagtegaal ID,Odze RD,Klimstra D,et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology,2020,76(2):182-188.
[21]
Aparicio T,Svrcek M,Zaanan A,et al. Small bowel adenocarcinoma phenotyping,a clinicobiological prognostic study[J]. Br J Cancer,2013,109(12):3057-3066.
[22]
American Joint Committee on Cancer. AJCC Cancer Staging Manual[M]. 8th ed. Berlin:Springer,2017.
[23]
Ciresi DL,Scholten DJ. The continuing clinical dilemma of primary tumors of the small intestine[J]. Am Surg,1995,61(8):698-702;discussion-703.
[24]
Ojha A,Zacherl J,Scheuba C,et al. Primary small bowel malignancies:single-center results of three decades[J]. J Clin Gastroenterol,2000,30(3):289-293.
[25]
Talamonti MS,Goetz LH,Rao S,et al. Primary cancers of the small bowel:analysis of prognostic factors and results of surgical management[J]. Arch Surg,2002,137(5):564-570; discussion 570-571.
[26]
Minardi AJ Jr.,Zibari GB,Aultman DF,et al. Small-bowel tumors[J].J Am Coll Surg,1998,186(6):664-668.
[27]
Halfdanarson TR,Mcwilliams RR,Donohue JH,et al. A single-institution experience with 491 cases of small bowel adenocarcinoma[J]. Am J Surg,2010,199(6):797-803.
[28]
Iddan G,Meron G,Glukhovsky A,et al. Wireless capsule endoscopy[J]. Nature,2000,405(6785):417.
[29]
Pennazio M,Spada C,Eliakim R,et al. Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders:European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline[J]. Endoscopy,2015,47(4):352-376.
[30]
Yano T,Yamamoto H. Endoscopic diagnosis of small bowel tumor[J].Cancers (Basel),2024,16(9):1704.
[31]
Kong H,Kim YS,Hyun JJ,et al. Limited ability of capsule endoscopy to detect normally positioned duodenal papilla[J]. Gastrointest Endosc,2006,64(4):538-541.
[32]
Fantasia S,Cortegoso Valdivia P,Kayali S,et al. The role of capsule endoscopy in the diagnosis and management of small bowel tumors:a narrative review[J]. Cancers(Basel),2024,16(2):262.
[33]
Rondonotti E,Koulaouzidis A,Georgiou J,et al. Small bowel tumours:update in diagnosis and management[J]. Curr Opin Gastroenterol,2018,34(3):159-164.
[34]
Segarajasingam DS,Hanley SC,Barkun AN,et al. Randomized controlled trial comparing outcomes of video capsule endoscopy with push enteroscopy in obscure gastrointestinal bleeding[J]. Can J Gastroenterol Hepatol,2015,29(2):85-90.
[35]
Overman MJ,Hu CY,Wolff RA,et al. Prognostic value of lymph node evaluation in small bowel adenocarcinoma:analysis of the surveillance,epidemiology,and end results database[J]. Cancer,2010,116(23):5374-5382.
[36]
Benson AB,Venook AP,Al-hawary MM,et al. Small bowel adenocarcinoma,version 1.2020,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2019,17(9):1109-1133.
[37]
Onkendi EO,Boostrom SY,Sarr MG,et al. 15-year experience with surgical treatment of duodenal carcinoma:a comparison of periampullary and extra-ampullary duodenal carcinomas[J]. J Gastrointest Surg,2012,16(4):682-691.
[38]
Raghav K,Overman MJ. Small bowel adenocarcinomas-existing evidence and evolving paradigms[J]. Nat Rev Clin Oncol,2013,10(9):534-544.
[39]
Ecker BL,Mcmillan MT,Datta J,et al. Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma:a propensity scorematched analysis[J]. Cancer,2016,122(5):693-701.
[40]
Zaanan A,Henriques J,Turpin A,et al. Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma:a large retrospective multicenter study[J]. JNCI Cancer Spectr,2023,7(5):pkad064.
[41]
Kelsey CR,Nelson JW,Willett CG,et al. Duodenal adenocarcinoma:patterns of failure after resection and the role of chemoradiotherapy[J].Int J Radiat Oncol Biol Phys,2007,69(5):1436-1441.
[42]
Meijer LL,Alberga AJ,De Bakker JK,et al. Outcomes and treatment options for duodenal adenocarcinoma:a systematic review and metaanalysis[J]. Ann Surg Oncol,2018,25(9):2681-2692.
[43]
Kitahara H,Honma Y,Ueno M,et al. Randomized phase III trial of post-operative chemotherapy for patients with stage I/II/III small bowel adenocarcinoma (JCOG1502C,J-BALLAD)[J]. Jpn J Clin Oncol,2019,49(3):287-290.
[44]
Khosla D,Dey T,Madan R,et al. Small bowel adenocarcinoma:an overview[J]. World J Gastrointest Oncol,2022,14(2):413-422.
[45]
Poultsides GA,Huang LC,Cameron JL,et al. Duodenal adenocarcinoma:clinicopathologic analysis and implications for treatment[J]. Ann Surg Oncol,2012,19(6):1928-1935.
[46]
Onkendi EO,Boostrom SY,Sarr MG,et al. Neoadjuvant treatment of duodenal adenocarcinoma:a rescue strategy[J]. J Gastrointest Surg,2012,16(2):320-324.
[47]
Yeung RS,Weese JL,Hoffman JP,et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study[J]. Cancer,1993,72(7):2124-2133.
[48]
Coia L,Hoffman J,Scher R,et al. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum[J]. Int J Radiat Oncol Biol Phys,1994,30(1):161-167.
[49]
Adam R,Chiche L,Aloia T,et al. Hepatic resection for noncolorectal nonendocrine liver metastases:analysis of 1,452 patients and development of a prognostic model[J]. Ann Surg,2006,244(4):524-535.
[50]
Bhamidipati D,Colina A,Hwang H,et al. Metastatic small bowel adenocarcinoma:role of metastasectomy and systemic chemotherapy[J]. ESMO Open,2021,6(3):100132.
[51]
Nishikawa Y,Horimatsu T,Oka S,et al. Outcomes of metastatic and unresectable small bowel adenocarcinoma in japan according to the treatment strategy:a nationwide observational study[J]. JCO Glob Oncol,2024,10:e2300392.
[52]
Rovers KP,De Bree E,Yonemura Y,et al. Treatment of peritoneal metastases from small bowel adenocarcinoma[J]. Int J Hyperthermia,2017,33(5):571-578.
[53]
Van Ouclheusden TR,Lemumens VE,Braam HJ,et al. Peritoneal metastases from small bowel cancer:results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands[J].Surgery,2015,157(6):1023-1027.
[54]
Saxena A,Valle SJ,Liauw W,et al. Recurrence and survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for small bowel adenocarcinoma[J]. Anticancer Res,2017,37(10):5737-5742.
[55]
Fernando DG,Sparapani R,Mogal H. Role of cytoreduction and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)in the treatment of peritoneal carcinomatosis from small bowel adenocarcinoma-a systematic review and meta-analysis[J]. J Surg Oncol,2024,Nov 17.
[56]
Liu Y,Yonemura Y,Levine EA,et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal metastases from a small bowel adenocarcinoma:multi-institutional experience[J].Ann Surg Oncol,2018,25(5):1184-1192.
[57]
Chen V,Jones M,Cohen L,et al. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in small bowel adenocarcinoma with peritoneal metastasis:a systematic review [J].Pleura Peritoneum,2022,7(4):159-167.
[58]
Saxena A,Valle SJ,Liauw W,et al. Recurrence and survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for small bowel adenocarcinoma[J]. Anticancer Res,2017,37(10):5737-5742.
[59]
Legué LM,Simkens GA,Creemers GJM,et al. Synchronous peritoneal metastases of small bowel adenocarcinoma:insights into an underexposed clinical phenomenon[J]. Eur J Cancer,2017,87:84-91.
[60]
Jigyasu D,Bedikian AY,Stroehlein JR. Chemotherapy for primary adenocarcinoma of the small bowel[J]. Cancer,1984,53(1):23-25.
[61]
Zhang L,Wang LY,Deng YM,et al. Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma:a three-center study from China[J]. J Buon,2011,16(4):689-696.
[62]
Aydin D,Sendur MA,Kefeli U,et al. Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma:report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO)[J]. J Buon,2016,21(5):1242-1249.
[63]
Zaanan A,Gauthier M,Malka D,et al. Second-line chemotherapy with fluorouracil,leucovorin,and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy:a multicenter AGEO study [J]. Cancer,2011,117(7):1422-1428.
[64]
Aldrich JD,Raghav KPS,Varadhachary GR,et al. Retrospective analysis of taxane-based therapy in small bowel adenocarcinoma[J].Oncologist,2019,24(6):e384-e386.
[65]
Overman MJ,Adam L,Raghav K,et al. Phase II study of nabpaclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer[J]. Ann Oncol,2018,29(1):139-144.
[66]
Takayoshi K,Kusaba H,Uenomachi M,et al. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer[J]. Cancer Chemoth Pharm,2017,80(2):333-342.
[67]
Gulhati P,Raghav K,Shroff R,et al. Phase II study of panitumumab in RAS wild-type metastatic adenocarcinoma of small bowel or ampulla of vater[J]. Oncologist,2018,23(3):277-e26.
[68]
Schrock AB,Devoe CE,Mcwilliams R,et al. Genomic profiling of small-bowel adenocarcinoma[J]. JAMA Oncol,2017,3(11):1546-1553.
[69]
中国临床肿瘤学会胃肠间质瘤专家委员会. 中国胃肠间质瘤诊断治疗共识(2017年版) [J]. 肿瘤综合治疗电子杂志,2018,4(1):31-43.
[70]
中国研究型医院学会消化道肿瘤专业委员会,中国医师协会外科医师分会多学科综合治疗专业委员会. 胃肠间质瘤多学科综合治疗协作组诊疗模式专家共识[J]. 中国实用外科杂志,2017,37(1):39-41.
[71]
中国临床肿瘤学会胃肠间质瘤专家委员会,中国抗癌协会胃肠间质瘤专业委员会,中国医师协会外科医师分会胃肠道间质瘤诊疗专业委员会. 小胃肠间质瘤诊疗中国专家共识(2020年版)[J]. 临床肿瘤学杂志,2020,25(4):349-355.
[72]
中国医师协会外科医师分会胃肠道间质瘤诊疗专业委员会,中华医学会外科学分会胃肠外科学组. 胃肠间质瘤规范化外科治疗中国专家共识(2018版)[J]. 中国实用外科杂志,2018,38(9):965-973.
[73]
Du CY,Zhou Y,Song C,et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib:a prospective randomised trial in China[J]. Eur J Cancer,2014,50(10):1772-1778.
[74]
陈晓,王雷,范崇熙,等. 原发性小肠淋巴瘤的临床、内镜特征及预后相关因素分析[J]. 空军航空医学,2024,41(5):411-416.Chen X,Wang L,Fan CX,et al. Clinical and endoscopic features,and prognostic factors of primary small intestinal lymphoma[J]. Aviation Medicine of Air Force,2024,41(5):411-416.
[75]
李坚,黄楠,肖泽彬,等. 小肠淋巴瘤的CT和MRI表现[J]. 临床放射学杂志,2015,34(11):1784-1789.Li J,Huang N,Xiao ZB,et al. CT and MR imaging features of small intestinal lymphomas[J]. Journal of Clinical Radiology,2015,34(11):1784-1789.
[76]
陈春茂,孙西河. 基于CT影像学特征构建原发性小肠淋巴瘤与间质瘤的鉴别诊断预测模型[J]. 潍坊医学院学报,2024,46(3):161-164.Chen CM,Sun XH. Construct predictive model in the differential diagnosis of small intestinal lymphoma and stromal tumor[J]. Journal of Shandong Second Medical University,2024,46(3):161-164.
[77]
田丰宇. 原发性小肠淋巴瘤临床与内镜特征的回顾性分析[D]. 济南:山东大学,2022.
[78]
曹皓阳,高青. 原发性小肠淋巴瘤诊治研究进展[J]. 现代医药卫生,2020,36(14):2202-2205.
[79]
Lens M,Bataille V,Krivokapic Z. Melanoma of the small intestine[J].Lancet Oncol,2009,10(5):516-521.
[80]
Gracas AM,Souza WP,Canut ACA,et al. Primary small bowel melanoma:a case report and review of literature[J]. Front Surg,2022,9:792243.
[81]
Aryan M,Al Diffalha S,Ahmed AM,et al. Small bowel melanoma:a double balloon enteroscopy case series [J]. Endoscopy,2022,55(S 01):E33-E34.
[82]
Kohoutova D,Worku D,Aziz H,et al. Malignant melanoma of the gastrointestinal tract:symptoms,diagnosis,and current treatment options[J]. Cells,2021,10(2):327.
[83]
Agrawal S,Mccarron EC,Gibbs JF,et al. Surgical management and outcome in primary adenocarcinoma of the small bowel[J]. Ann Surg Oncol,2007,14(8):2263-2269.
[1] 王昭珏, 朱庆莉, 李文波, 杨红, 钱家鸣, 李建初. 超声医学科在中国炎症性肠病多学科诊疗中实施的现况调查[J/OL]. 中华医学超声杂志(电子版), 2025, 22(02): 131-138.
[2] 蒙燕, 唐如冰, 蒋奕, 陆华, 苏玉兰, 张琼, 何英煜. 基于多学科协作的预防性淋巴管-静脉吻合术在乳腺癌腋窝淋巴结清扫患者中的应用[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(03): 204-207.
[3] 李明娟, 林陈心子, 吴姝萱, 万启龙. 合并牙列缺损的牙颌面畸形的病因、临床特点及诊疗策略[J/OL]. 中华口腔医学研究杂志(电子版), 2025, 19(01): 1-8.
[4] 邱荣敏, 胡小毅, 王芳, 钟玉钰, 朱光宇, 欧阳珊. 以需求为导向的多学科联合教学在口腔急诊规范化培训课程中的应用[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(05): 325-329.
[5] 赵海涛. 进展期胆管癌治疗探索及展望[J/OL]. 中华普通外科学文献(电子版), 2025, 19(02): 110-110.
[6] 董振阳, 瞿旻, 王燕, 张韻, 高旭. 序贯多学科会诊模式在前列腺癌全程管理中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(02): 152-158.
[7] 罗添龙, 贺情情, 黄海. 泌尿功能障碍慢性病的长期综合管理和持久康复实践[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 21-26.
[8] 吴伟宙, 王琼仁, 詹雄宇, 郑明星, 李亚县. 广东省医学会泌尿外科疑难病例多学科会诊(第16期)——左肾肉瘤样癌[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 525-529.
[9] 邱雨豪, 黄金向, 朱小轩, 罗峰, 黄河, 姚晖, 汪雪. 多学科诊疗联合加速康复外科模式在食管裂孔疝诊疗中的应用[J/OL]. 中华疝和腹壁外科杂志(电子版), 2025, 19(01): 56-62.
[10] 任甜甜, 张玉慧, 祁玲霞, 朱梅冬, 胡佳. 多学科疼痛管理对胸腔镜肺叶切除术后胸痛及应激反应的影响分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 630-633.
[11] 王微, 丁霖, 陈茜, 呼延欣, 闫蓓. 综合治疗对慢性阻塞性肺疾病的疗效及转归影响分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 621-624.
[12] 张龙, 孙善柯, 徐伟, 李文柱, 李俊达, 池涌泉, 何广胜, 成峰, 王学浩, 饶建华. 腹腔镜脾切除治疗血液系统疾病的临床疗效分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 870-875.
[13] 武帅, 吴佼星, 王方舟, 杨沛泽, 董顺斌, 王铮, 仵正. 胰腺腺泡细胞癌诊断与治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 487-491.
[14] 陆知非, 华永飞, 姜哲康, 高过, 江寅, 王高卿. 初始不可切除肝癌转化治疗的影响因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(03): 268-274.
[15] 刘晓梅, 罗永梅, 傅瑜. 基于信息化老年综合评估的多学科管理护理模式在脑梗死患者中的应用效果[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(03): 255-264.
阅读次数
全文


摘要